ARCHIVES

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

NCAB Committee Approves Concepts For Recompetition Of CIDAC, Two Other Contracts

July 1, 1983

Judge Rules First Amendment Protects Distribution Of Off-Label Use Information

August 14, 1998

NRC considering “Escalated” Enforcement Action Against NIH

February 2, 1996

NCI Objections Delay GAO Report On Cancer Control

March 7, 1980

Hepatitis B Vaccine Almost Ready, Blumberg Tells Science Writers

April 10, 1981

Four DCCP Contracts Costing $9 Million Approved By Board for Recompetition

June 10, 1983